Trials / Completed
CompletedNCT02608515
A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease
A Retrospective Chart Review Study of the Outcomes of Second Line Therapy With LEnalidomide/Dexamethasone in Greek Patients With Relapsed/Refractory Multiple MyEloma and the Treatment PatterNs Following Progressive Disease, "The LEGEND Study"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 207 (actual)
- Sponsor
- Genesis Pharma S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This non-interventional retrospective chart review study aims to evaluate the clinical outcomes of patients with RRMM receiving lenalidomide/dexamethasone (Len/Dex) treatment at 1st relapse and the treatment patterns following progressive disease as part of the routine clinical practice in Greece.
Conditions
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2015-11-18
- Last updated
- 2018-05-22
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT02608515. Inclusion in this directory is not an endorsement.